Drug Trial Radar · NCT06212076
Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients
Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jul 11, 2024
Primary completion
Jul 9, 2027
Study completion Jul 9, 2027
Sponsor
- Lead sponsor
- Nanjing Immunophage Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) characteristics and initial anti-tumor activity of IPG1094 in patients with advanced solid tumors. The study will be conducted in two parts: dose escalation phase (Part A) and expansion phase (Part B).
Conditions
- Solid Tumor
Interventions
IPG1094Drug
IPG1094 Activity: An inhibitor of macrophage migration inhibitory factor (MIF) Dosage form: Tablet Strength: 50 mg and 100 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary endpointTime frame: Up to 6 months
- Primary endpointTime frame: Up to 2 months
- Primary endpointTime frame: Up to 3 months
- Primary endpointTime frame: Up to 8 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Shanghai GoBroad Cancer Hospital China Pharmaceutical University
Shanghai, China · Recruiting
Shanghai General Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.